Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Retained Earnings (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Retained Earnings for 4 consecutive years, with -$711.3 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 17545.75% to -$711.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$711.3 million through Dec 2025, down 17545.75% year-over-year, with the annual reading at -$711.3 million for FY2025, 17545.75% down from the prior year.
  • Retained Earnings hit -$711.3 million in Q4 2025 for Taysha Gene Therapies, down from -$1.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$251000.0 in Q1 2024 to a low of -$711.3 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$324.4 million across 4 years, with a median of -$373.7 million in 2022.
  • Biggest five-year swings in Retained Earnings: surged 99.94% in 2024 and later tumbled 248425.9% in 2025.
  • Year by year, Retained Earnings stood at -$401.4 million in 2022, then decreased by 27.79% to -$513.0 million in 2023, then skyrocketed by 99.21% to -$4.0 million in 2024, then tumbled by 17545.75% to -$711.3 million in 2025.
  • Business Quant data shows Retained Earnings for TSHA at -$711.3 million in Q4 2025, -$1.1 million in Q3 2025, and -$699000.0 in Q2 2025.